The short version
Tirzepatide is a once weekly injectable medication that copies the action of two hormones your gut releases after you eat, GIP and GLP-1. Both hormones signal to the brain that you have eaten, and the FDA-approved prescribing information for Zepbound® describes tirzepatide as activating the receptors for both. That dual action is what sets it apart from semaglutide, which acts on the GLP-1 receptor alone. This guide explains the mechanism as the label describes it, what the reference trial found, and what a licensed provider weighs before prescribing.
This is general information and not medical advice. The label and trial described here concern Zepbound®, the FDA-approved product. Personalized Compounded tirzepatide, which Bodi Envi’s programs may include, is not FDA-approved and was not studied in that trial. Your licensed provider is the person to ask about your own treatment.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Two hormones, one molecule
After a meal, the gut releases several hormones that tell the rest of the body food has arrived. Two of them are incretins, so called because they increase insulin release when blood sugar rises. Glucagon-like peptide-1, GLP-1, is the better known. The Zepbound® label describes it as a physiological regulator of appetite and caloric intake. Glucose-dependent insulinotropic polypeptide, GIP, is the second. The label says that nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake.
Tirzepatide is a single molecule engineered to act on the receptors for both. According to the Zepbound® label, it selectively binds to and activates both the GIP and GLP-1 receptors, which are the targets for the natural hormones. The label notes that both receptors are found in areas of the brain involved in appetite regulation, and that animal studies show tirzepatide distributes to and activates neurons in brain regions involved in the regulation of appetite and food intake.
In plain terms, the medication strengthens the signals that tell you that you have eaten enough. People taking it generally describe feeling full sooner and staying full longer. It also slows the rate at which the stomach empties, which is part of the fullness effect and is also, per the label, the reason it can affect how oral medications are absorbed and why nausea is its most common side effect.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Why the dual action is thought to matter
The label does not claim a precise mechanism for why two receptors do more than one, and this guide does not either. What the label does say is that tirzepatide lowers body weight with greater fat mass loss than lean mass loss, and that the addition of GIP may further contribute to the regulation of food intake. The trial results below are the evidence that the combination produces a substantial effect; how much of that effect belongs to each receptor is a research question, not a settled fact.
One consequence is worth spelling out. Because tirzepatide activates the GLP-1 receptor, it belongs to the same broad family as semaglutide and shares that family’s label warnings: the boxed warning about thyroid C-cell tumours in rodent studies, and the warnings about pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration and severe gastrointestinal reactions. The Zepbound® label also states that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. The safety guide on this site goes through the warnings as the label states them.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Why it is taken once a week
Natural GLP-1 and GIP are broken down within minutes. The Zepbound® label explains that tirzepatide contains a C20 fatty diacid, a fatty acid chain, that enables it to bind to albumin, the most abundant protein in blood, and that this binding prolongs its half-life to approximately five days. The label’s pharmacokinetics section adds that steady-state concentrations are reached after four weeks of once weekly dosing, that exposure increases in proportion to the dose, that the medication reaches its peak in the blood at a median of 24 hours after injection, and that similar exposure is achieved whether it is injected in the abdomen, thigh or upper arm.
Those figures explain two things a patient notices. It takes several weeks on a given dose for the level in the body to settle, which is one reason the label’s escalation steps are spaced at least four weeks apart. And a single missed dose does not remove the medication from the body at once; the label says that if a dose is missed, it may be taken within four days, and otherwise skipped, with weekly dosing then resumed on the usual day. Both are descriptions of the approved product, not instructions, and with a compounded prescription your provider’s plan governs. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the label says about dosing
The Zepbound® label sets a starting dose of 2.5 mg injected under the skin once weekly for four weeks, and states that 2.5 mg is for treatment initiation and is not approved as a maintenance dose. After four weeks the dose increases to 5 mg, and may then be increased in 2.5 mg steps after at least four weeks on the current dose. The label lists 5 mg, 10 mg and 15 mg as the maintenance doses for weight reduction, 15 mg as the maximum, and says that if a maintenance dose is not tolerated a lower one should be considered. The reason it gives for the whole schedule is to reduce the risk of gastrointestinal adverse reactions.
That is what the label describes for the branded product. A compounded prescription is measured from a vial rather than a fixed dose pen, and the provider who writes it sets your starting dose, the timing of any increase, and whether to hold or lower a dose. Bodi Envi’s published pricing does not increase based solely on dosage strength, so on its programs that decision is clinical and not financial.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What SURMOUNT-1 found
The reference trial for tirzepatide in weight management is SURMOUNT-1, published by Jastreboff and colleagues in the New England Journal of Medicine in 2022. According to the abstract on PubMed, the trial enrolled 2,539 adults with a body mass index of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, and assigned them equally to once weekly tirzepatide at 5 mg, 10 mg or 15 mg, or placebo, for 72 weeks including a 20 week dose escalation period. At baseline the mean body weight was 104.8 kg and the mean body mass index was 38.
The mean percentage change in weight at week 72 was 15.0 percent with 5 mg, 19.5 percent with 10 mg, 20.9 percent with 15 mg and 3.1 percent with placebo. The proportion of participants who lost at least 5 percent of their body weight was 85, 89 and 91 percent across the three doses against 35 percent with placebo, and half or more of the two higher dose groups lost 20 percent or more against 3 percent with placebo. The most common adverse events were gastrointestinal, mostly mild to moderate, and occurred primarily during dose escalation. Adverse events led to discontinuation in 4.3, 7.1 and 6.2 percent of the three tirzepatide groups and 2.6 percent of the placebo group.
Three caveats go with those numbers. The trial studied Zepbound® at its approved doses, not a compounded version. The figures are means across thousands of people, and the range of individual results around them was wide. And the trial ran for 72 weeks alongside a reduced calorie diet and increased physical activity, which the label says the medication is to be used in combination with. Individual experiences and outcomes vary.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What this means when you talk to a provider
A licensed healthcare provider determines whether treatment is appropriate for each individual patient. Understanding the mechanism helps you ask better questions rather than answer them yourself.
Because tirzepatide acts on appetite signals, a provider will want to know about your eating patterns and your weight history, and the approved product’s indication, adults with obesity or with overweight and a weight-related condition, frames who the trials studied. Because it slows stomach emptying, a provider will ask about oral medications you take, especially ones with a narrow therapeutic range, and the Zepbound® label advises people who use oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase. Because it lowers blood sugar, a provider will ask about diabetes and any insulin or sulfonylurea. And because of the label’s contraindications and warnings, a provider will ask about thyroid cancer in your family, pancreatitis, gallbladder disease, kidney problems, diabetic eye disease and any planned surgery under anesthesia.
None of that is a barrier for its own sake. It is the information the label says a prescriber needs, and the assessment asks for it so the provider can decide safely.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How Bodi Envi’s program approaches it
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer. Clinical services for applicable programs are provided by Wasef Health, PC, whose licensed providers independently evaluate patients and decide whether treatment is appropriate. Prescriptions are dispensed by third party U.S. 503A licensed compounding pharmacies; VialsRx is the current pharmacy partner for applicable GLP-1 prescriptions, and availability may vary by program and location.
The personalized compounded tirzepatide program is published on the Plans page at $229 per month billed monthly, $219 per month on a three month plan paid as $657, $205 per month on a six month plan paid as $1,230, and $175 per month on a twelve month plan paid as $2,100, with the assessment, provider review, care team messaging, a GLP-1 ebook and diet plan, and the medication when prescribed included. Personalized compounded tirzepatide is not FDA-approved and is not equivalent to Zepbound® or Mounjaro®; the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Medication is included only when a licensed provider determines treatment is appropriate and issues a prescription, and completing an assessment does not guarantee one.
This guide is general information and not medical advice. The mechanism and trial results describe the FDA-approved product, compounded versions were not studied, and your licensed provider is the person to ask about your own treatment.